ABEO vs. PRPH, GNLX, PMVP, ALLK, DMAC, SLS, ORMP, BTAI, MIST, and IOBT
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include ProPhase Labs (PRPH), Genelux (GNLX), PMV Pharmaceuticals (PMVP), Allakos (ALLK), DiaMedica Therapeutics (DMAC), SELLAS Life Sciences Group (SLS), Oramed Pharmaceuticals (ORMP), BioXcel Therapeutics (BTAI), Milestone Pharmaceuticals (MIST), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
ProPhase Labs (NASDAQ:PRPH) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends.
Abeona Therapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -37.81%. Abeona Therapeutics' return on equity of -29.83% beat ProPhase Labs' return on equity.
ProPhase Labs currently has a consensus price target of $11.00, indicating a potential upside of 120.00%. Abeona Therapeutics has a consensus price target of $36.00, indicating a potential upside of 1,042.86%. Given ProPhase Labs' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than ProPhase Labs.
ProPhase Labs has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.
9.5% of ProPhase Labs shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 26.1% of ProPhase Labs shares are held by insiders. Comparatively, 5.3% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Abeona Therapeutics received 399 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 70.27% of users gave Abeona Therapeutics an outperform vote while only 50.44% of users gave ProPhase Labs an outperform vote.
In the previous week, Abeona Therapeutics had 6 more articles in the media than ProPhase Labs. MarketBeat recorded 14 mentions for Abeona Therapeutics and 8 mentions for ProPhase Labs. Abeona Therapeutics' average media sentiment score of 1.46 beat ProPhase Labs' score of -0.14 indicating that ProPhase Labs is being referred to more favorably in the media.
ProPhase Labs has higher revenue and earnings than Abeona Therapeutics. ProPhase Labs is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Abeona Therapeutics beats ProPhase Labs on 9 of the 16 factors compared between the two stocks.
Get Abeona Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abeona Therapeutics Competitors List
Related Companies and Tools
